Novo Nordisk As Stock Performance
| NVO Stock | USD 77.87 0.96 1.22% |
The company secures a Beta (Market Risk) of 0.0497, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Novo Nordisk's returns are expected to increase less than the market. However, during the bear market, the loss of holding Novo Nordisk is expected to be smaller as well. At this point, Novo Nordisk AS has a negative expected return of -0.4%. Please make sure to verify Novo Nordisk's value at risk, rate of daily change, as well as the relationship between the Rate Of Daily Change and relative strength index , to decide if Novo Nordisk AS performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Novo Nordisk AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in March 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (1.22) | Five Day Return (3.89) | Year To Date Return (11.03) | Ten Year Return 252.51 | All Time Return 48.6 K |
Forward Dividend Yield 0.0208 | Payout Ratio | Last Split Factor 2:1 | Forward Dividend Rate 1.62 | Dividend Date 2025-04-08 |
1 | Eli Lilly strikes deal for cancer treatment, gives timeline for weight loss pill | 01/13/2025 |
2 | NVO Investors Have Opportunity to Lead Novo Nordisk AS Securities Fraud Lawsuit | 02/07/2025 |
3 | NVO Investors Have Opportunity to Lead Novo Nordisk AS Securities Fraud Lawsuit with the Schall Law Firm | 02/10/2025 |
4 | Novo Nordisk AS Trading Down 0.4 percent Heres What Happened | 02/11/2025 |
5 | Pharma-linked group wins over media | 02/12/2025 |
6 | Novo Nordisk AS Faces Class Action Lawsuit Over Securities Fraud Allegations | 02/13/2025 |
7 | NVO STOCK NEWS NVO Shareholders with Large Losses Should Contact Robbins LLP for Information ... | 02/14/2025 |
| Begin Period Cash Flow | 14.4 B |
Novo |
Novo Nordisk Relative Risk vs. Return Landscape
If you would invest 10,263 in Novo Nordisk AS on November 19, 2024 and sell it today you would lose (2,476) from holding Novo Nordisk AS or give up 24.13% of portfolio value over 90 days. Novo Nordisk AS is generating negative expected returns assuming volatility of 3.1916% on return distribution over 90 days investment horizon. In other words, 28% of stocks are less volatile than Novo, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Novo Nordisk Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novo Nordisk's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Novo Nordisk AS, and traders can use it to determine the average amount a Novo Nordisk's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1248
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NVO |
Estimated Market Risk
| 3.19 actual daily | 28 72% of assets are more volatile |
Expected Return
| -0.4 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Novo Nordisk is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novo Nordisk by adding Novo Nordisk to a well-diversified portfolio.
Novo Nordisk Fundamentals Growth
Novo Stock prices reflect investors' perceptions of the future prospects and financial health of Novo Nordisk, and Novo Nordisk fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novo Stock performance.
| Return On Equity | 0.81 | ||||
| Return On Asset | 0.22 | ||||
| Profit Margin | 0.35 % | ||||
| Operating Margin | 0.50 % | ||||
| Current Valuation | 357.75 B | ||||
| Shares Outstanding | 3.36 B | ||||
| Price To Earning | 37.42 X | ||||
| Price To Book | 17.29 X | ||||
| Price To Sales | 1.21 X | ||||
| Revenue | 290.4 B | ||||
| Gross Profit | 246.84 B | ||||
| EBITDA | 147.94 B | ||||
| Net Income | 100.99 B | ||||
| Cash And Equivalents | 37.47 B | ||||
| Cash Per Share | 16.57 X | ||||
| Total Debt | 102.79 B | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 0.92 X | ||||
| Book Value Per Share | 32.31 X | ||||
| Cash Flow From Operations | 120.97 B | ||||
| Earnings Per Share | 3.15 X | ||||
| Market Capitalization | 350 B | ||||
| Total Asset | 465.8 B | ||||
| Retained Earnings | 144.45 B | ||||
| Working Capital | (56.63 B) | ||||
| Current Asset | 8.03 B | ||||
| Current Liabilities | 5.95 B | ||||
About Novo Nordisk Performance
By examining Novo Nordisk's fundamental ratios, stakeholders can obtain critical insights into Novo Nordisk's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Novo Nordisk is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 334.89 | 215.38 | |
| Return On Tangible Assets | 0.28 | 0.15 | |
| Return On Capital Employed | 0.52 | 0.29 | |
| Return On Assets | 0.22 | 0.14 | |
| Return On Equity | 0.70 | 0.74 |
Things to note about Novo Nordisk AS performance evaluation
Checking the ongoing alerts about Novo Nordisk for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Novo Nordisk AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Novo Nordisk AS generated a negative expected return over the last 90 days | |
| Novo Nordisk AS has high historical volatility and very poor performance | |
| Novo Nordisk AS has 102.79 B in debt with debt to equity (D/E) ratio of 0.34, which is OK given its current industry classification. Novo Nordisk AS has a current ratio of 0.9, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for Novo to invest in growth at high rates of return. | |
| Latest headline from gurufocus.com: NVO STOCK NEWS NVO Shareholders with Large Losses Should Contact Robbins LLP for Information ... |
- Analyzing Novo Nordisk's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novo Nordisk's stock is overvalued or undervalued compared to its peers.
- Examining Novo Nordisk's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novo Nordisk's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novo Nordisk's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novo Nordisk's stock. These opinions can provide insight into Novo Nordisk's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.292 | Dividend Share 11.4 | Earnings Share 3.15 | Revenue Per Share | Quarterly Revenue Growth 0.301 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.